Abstract
The coronavirus disease 2019 (COVID-19) pandemic caused by infection with SARS-CoV-2 has led to more than 600 000 deaths worldwide. Patients with severe disease often experience acute respiratory distress characterized by upregulation of multiple cytokines. Immunomodulatory biological therapies are being evaluated in clinical trials for the management of the systemic inflammatory response and pulmonary complications in patients with advanced stages of COVID-19. In this review, we summarize the clinical pharmacology considerations in the development of immunomodulatory therapeutic proteins for mitigating the heightened inflammatory response identified in COVID-19.
Author supplied keywords
Cite
CITATION STYLE
Ji, P., Chen, J., Golding, A., Nikolov, N. P., Saluja, B., Ren, Y. R., & Sahajwalla, C. G. (2020, October 1). Immunomodulatory Therapeutic Proteins in COVID-19: Current Clinical Development and Clinical Pharmacology Considerations. Journal of Clinical Pharmacology. Blackwell Publishing Inc. https://doi.org/10.1002/jcph.1729
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
